A Study of Picankibart in Patients With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Picankibart in Patients With Active Psoriatic Arthritis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
222 participants
Dec 18, 2025
INTERVENTIONAL
Conditions
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with active psoriatic arthritis (PsA). The study consists of two stages: Phase II dose-finding (n=90) and Phase III confirmatory (n=132). Participants will receive subcutaneous (SC) injections of either picankibart (200mg) or placebo with different dosing schedules, with placebo crossover to active treatment at Week 26. The Phase II portion will identify optimal dosing for Phase III, which will confirm efficacy. The study will evaluate improvements in joint symptoms, physical function, quality of life, and skin manifestations. Primary endpoint is percentage of participants who achieved an American College of Rheumatology (ACR) 20 Response at Week 24.
Eligibility
Inclusion Criteria6
- Age 18-75 years
- Diagnosed with PsA for ≥3 months, and meeting Classification Criteria for Psoriatic Arthritis (CASPAR) at screening
- Having active PsA: ≥3 tender joints and ≥3 swollen joints at screening and baseline
- Having active plaque psoriasis (≥1 lesion ≥2cm) or nail psoriasis, or a documented history of plaque psoriasis
- Inadequate response or intolerance to prior NSAIDs or non-biologic DMARDs
- Stable doses of protocol permitted background therapy (if any)
Exclusion Criteria7
- Other inflammatory conditions that may affect the evaluation of the study drug
- Prior treatment with \>2 biologic agents
- Recent use of prohibited medications (specific washout periods apply)
- Non-plaque psoriasis forms or drug-induced psoriasis
- Severe, progressive, or uncontrolled renal, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, hematological, rheumatic (excluding PsA), psychiatric, or genitourinary conditions
- Significant laboratory abnormalities
- Pregnancy or breastfeeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Placebo administered SC at each scheduled dosing timepoint.
Picankibart administered SC at each scheduled dosing timepoint.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07295509